论文部分内容阅读
慢性骨髓性白血病(CML)的根治方法首推骨髓移植,且以用 HLA 一致的同胞兄妹的骨髓进行同种骨髓移植效果良好。一、同种骨髓移植的效果根据西雅图骨髓移植组、国际骨髓移植注册组织(IBMTR)和法国骨髓移植研究组(GEGMO)的疗效报告,其移植前基本上均用环磷酰胺(CY)加全身放射线照射(TBI),仅在移植时疾病所处阶段和采用方法稍有不同,而移植前不同的前处置对预后无影响。预防移植物抗宿主病(GVHD)的方法,主要采用环孢菌素 A(CSA)、氨甲喋呤(MTX)。目前尚没有新的方法超过这两种药物。同种骨髓移植的结果表明,在第一慢性阶段移植的病例,长期生存率为55～65%,复发率为19～24%。通过多变量分析表明了以下几个重要问题。
Bone marrow transplantation is the first radical treatment of chronic myeloid leukemia (CML), and allogeneic bone marrow transplantation with bone marrow from sibling siblings with HLA is effective. First, the effect of allogeneic bone marrow transplantation According to the Seattle bone marrow transplantation group, the International Marrow Transplant Registration Group (IBMTR) and the French bone marrow transplant research group (GEGMO) efficacy report, before its transplantation are basically used cyclophosphamide (CY) plus body Radiation exposure (TBI) is only slightly different at the time of transplantation and the method of administration, whereas different pre-transplant interventions have no effect on prognosis. Methods to prevent graft versus host disease (GVHD) are mainly cyclosporin A (CSA) and methotrexate (MTX). There are no new ways to surpass these two drugs. The results of allogeneic bone marrow transplantation showed that the long-term survival rate was 55-65% and the recurrence rate was 19-24% in the cases of the first chronic phase transplantation. Multivariate analysis shows the following important issues.